These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 31764978

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y, Vargas HM.
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [Abstract] [Full Text] [Related]

  • 3. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
    Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G.
    Cell Rep; 2018 Sep 25; 24(13):3582-3592. PubMed ID: 30257217
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F, Pourrier M, Strauss DG, Stockbridge N, Pang L.
    Toxicol Sci; 2020 Apr 01; 174(2):254-265. PubMed ID: 32040191
    [Abstract] [Full Text] [Related]

  • 7. Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites.
    Lu HR, Zeng H, Kettenhofen R, Guo L, Kopljar I, van Ammel K, Tekle F, Teisman A, Zhai J, Clouse H, Pierson J, Furniss M, Lagrutta A, Sannajust F, Gallacher DJ.
    Toxicol Sci; 2019 Aug 01; 170(2):345-356. PubMed ID: 31020317
    [Abstract] [Full Text] [Related]

  • 8. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D, Stohlman J, Dang Q, Strauss DG, Blinova K.
    Toxicol Sci; 2019 Jul 01; 170(1):167-179. PubMed ID: 30912807
    [Abstract] [Full Text] [Related]

  • 9. The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Hortigon-Vinagre MP, Zamora V, Burton FL, Green J, Gintant GA, Smith GL.
    Toxicol Sci; 2016 Dec 01; 154(2):320-331. PubMed ID: 27621282
    [Abstract] [Full Text] [Related]

  • 10. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T, Moriyama Y, Taniguchi T, Maeda S, Ando H, Uda T, Otabe K, Oguchi M, Shimizu S, Saito H, Toratani A, Asayama M, Yamamoto W, Matsumoto E, Saji D, Ohnaka H, Miyamoto N.
    J Pharmacol Toxicol Methods; 2017 Dec 01; 85():73-81. PubMed ID: 28163191
    [Abstract] [Full Text] [Related]

  • 11. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
    Yamazaki D, Kitaguchi T, Ishimura M, Taniguchi T, Yamanishi A, Saji D, Takahashi E, Oguchi M, Moriyama Y, Maeda S, Miyamoto K, Morimura K, Ohnaka H, Tashibu H, Sekino Y, Miyamoto N, Kanda Y.
    J Pharmacol Sci; 2018 Apr 01; 136(4):249-256. PubMed ID: 29555184
    [Abstract] [Full Text] [Related]

  • 12. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X, Papoian T.
    J Appl Toxicol; 2018 Sep 01; 38(9):1166-1176. PubMed ID: 29484688
    [Abstract] [Full Text] [Related]

  • 13. Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes.
    Yanagida S, Satsuka A, Hayashi S, Ono A, Kanda Y.
    Biol Pharm Bull; 2022 Sep 01; 45(7):940-947. PubMed ID: 35786601
    [Abstract] [Full Text] [Related]

  • 14. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A, Juhasz K, Thomas U, Stölzle-Feix S, Becker N, Dörr L, Beckler M, Bot C, George M, Fertig N.
    J Pharmacol Toxicol Methods; 2016 Sep 01; 81():223-32. PubMed ID: 27084108
    [Abstract] [Full Text] [Related]

  • 15. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM, Campbell K, Mironov S, Jiang J, Mundada L, Guerrero-Serna G, Jalife J, Herron TJ.
    Sci Rep; 2017 Oct 23; 7(1):13834. PubMed ID: 29061979
    [Abstract] [Full Text] [Related]

  • 16. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y, Yamazaki D, Osada T, Yoshinaga T, Sawada K.
    J Pharmacol Sci; 2018 Dec 23; 138(4):233-239. PubMed ID: 30415824
    [Abstract] [Full Text] [Related]

  • 17. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J, Wei F, Cai C, Lyn-Cook B, Pang L.
    Toxicol Sci; 2019 Feb 01; 167(2):360-374. PubMed ID: 30247688
    [Abstract] [Full Text] [Related]

  • 18. Human Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets Expressing Genetically Encoded Voltage Indicator for Pharmacological and Arrhythmia Studies.
    Shaheen N, Shiti A, Huber I, Shinnawi R, Arbel G, Gepstein A, Setter N, Goldfracht I, Gruber A, Chorna SV, Gepstein L.
    Stem Cell Reports; 2018 Jun 05; 10(6):1879-1894. PubMed ID: 29754959
    [Abstract] [Full Text] [Related]

  • 19. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
    Ando H, Yoshinaga T, Yamamoto W, Asakura K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y.
    J Pharmacol Toxicol Methods; 2017 Jun 05; 84():111-127. PubMed ID: 27956204
    [Abstract] [Full Text] [Related]

  • 20. Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters.
    Kilfoil P, Feng SL, Bassyouni A, Lee T, Leishman D, Li D, MacEwan DJ, Sharma P, Watt ED, Jenkinson S.
    Eur J Pharmacol; 2021 Dec 05; 912():174584. PubMed ID: 34678241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.